SCHEMBL17298901

SCHEMBL17298901

Cc1ccc(CC(=O)NCC(F)(F)F)cn1

nearest known ligand 0.45

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.44
POLB P06746 2/20 0.44
KDM4E B2RXH2 2/20 0.43
GAA P10253 1/20 0.43
PARP14 Q460N5 1/20 0.41
SMN1; SMN2 Q16637 2/20 0.40
TSHR P16473 1/20 0.40
VNN1 O95497 1/20 0.40
GABRA1 P14867 2/20 0.40
JAK1 P23458 1/20 0.40
L3MBTL1 Q9Y468 2/20 0.40
KMT2A Q03164 1/20 0.39
SCN9A Q15858 1/20 0.39
CCNE1 P24864 1/20 0.38
CDK2 P24941 1/20 0.38
GSK3B P49841 1/20 0.38
PTPRZ1 P23471 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20275645 0.81 CCNE1 (0.46) LMNAKDM4EPARP14SMN1; SMN2TSHR
SCHEMBL16994745 0.80 KMT2A (0.59) LMNAPOLBGAASMN1; SMN2L3MBTL1
SCHEMBL2827343 0.80 CYP1A2 (0.58) PARP14SMN1; SMN2TSHRGABRA1
SCHEMBL24589251 0.78 TSHR (0.46) LMNAKDM4EGAAPARP14SMN1; SMN2
SCHEMBL4482901 0.76 LMNA (0.64) LMNAPOLBKDM4ESMN1; SMN2JAK1
SCHEMBL5423407 0.76 KDM4E (0.60) KDM4EKMT2A
SCHEMBL21178388 0.73 PTPRZ1 (0.46) LMNAPOLBKDM4EGAASMN1; SMN2
SCHEMBL25467700 0.73 L3MBTL1 (0.41) LMNAPOLBKDM4EGAASMN1; SMN2
SCHEMBL575044 0.72 GABRP (0.61) LMNAPOLBKDM4EGAASMN1; SMN2
SCHEMBL10123136 0.72 TSHR (0.50) LMNAPOLBKDM4EGAAPARP14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10300067-B2 Tetrahydropyridopyrimidine compound or salt thereof TAIHO PHARMACEUTICAL CO., LTD. (JP) 2019-05-28 US disclosed
US-20180161331-A1 NOVEL TETRAHYDROPYRIDOPYRIMIDINE COMPOUND OR SALT THEREOF TAIHO PHARMACEUTICAL CO., LTD. (JP) 2018-06-14 US disclosed
US-9889136-B2 Tetrahydropyridopyrimidine compound or salt thereof TAIHO PHARMACEUTICAL CO., LTD. (JP) 2018-02-13 US disclosed
US-9662333-B2 Tetrahydropyridopyrimidine compound or salt thereof TAIHO PHARMACEUTICAL CO., LTD. (JP) 2017-05-30 US disclosed
EP-3150599-A1 NOVEL TETRAHYDROPYRIDOPYRIMIDINE COMPOUND OR SALT THEREOF Taiho Pharmaceutical Co., Ltd. (JP) 2017-04-05 EP disclosed
US-20160310496-A1 NOVEL TETRAHYDROPYRIDOPYRIMIDINE COMPOUND OR SALT THEREOF TAIHO PHARMACEUTICAL CO., LTD. (JP) 2016-10-27 US disclosed
US-20160244444-A1 NOVEL TETRAHYDROPYRIDOPYRIMIDINE COMPOUND OR SALT THEREOF TAIHO PHARMACEUTICAL CO., LTD. (JP) 2016-08-25 US disclosed
WO-2015182712-A1 NOVEL TETRAHYDROPYRIDOPYRIMIDINE COMPOUND OR SALT THEREOF 大鵬薬品工業株式会社 2015-12-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180161331-A1 NOVEL TETRAHYDROPYRIDOPYRIMIDINE COMPOUND OR SALT THEREOF NR5A1, CYP17A1, AR LMNA 4805/4885POLB 2344/4885KDM4E 1995/4885
US-10300067-B2 Tetrahydropyridopyrimidine compound or salt thereof NR5A1, CYP17A1, DPYD LMNA 4752/4885POLB 1616/4885KDM4E 2393/4885
US-20160310496-A1 NOVEL TETRAHYDROPYRIDOPYRIMIDINE COMPOUND OR SALT THEREOF NR5A1, CYP17A1, AR LMNA 4805/4885POLB 2344/4885KDM4E 1995/4885
US-20160244444-A1 NOVEL TETRAHYDROPYRIDOPYRIMIDINE COMPOUND OR SALT THEREOF AR, NR5A1, NR5A2 LMNA 4865/4885POLB 2649/4885KDM4E 1358/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.